The gene therapy also failed a key efficacy endpoint in the SRP ... In a statement, the FDA said it had opted for the broad label for Elevidys based on “the totality of the evidence, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback